Target Price | $71.40 |
Price | $59.05 |
Potential |
20.91%
register free of charge
|
Number of Estimates | 14 |
14 Analysts have issued a price target Protagonist Therapeutics, Inc. 2026 .
The average Protagonist Therapeutics, Inc. target price is $71.40.
This is
20.91%
register free of charge
$86.10
45.81%
register free of charge
$46.46
21.32%
register free of charge
|
|
A rating was issued by 18 analysts: 16 Analysts recommend Protagonist Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Protagonist Therapeutics, Inc. stock has an average upside potential 2026 of
20.91%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 434.43 | 58.43 |
624.05% | 86.55% | |
EBITDA Margin | 58.87% | -250.12% |
139.10% | 524.88% | |
Net Margin | 63.35% | -214.56% |
148.13% | 438.72% |
14 Analysts have issued a sales forecast Protagonist Therapeutics, Inc. 2025 . The average Protagonist Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Protagonist Therapeutics, Inc. EBITDA forecast 2025. The average Protagonist Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Protagonist Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Protagonist Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 4.23 | -2.02 |
404.32% | 147.75% | |
P/E | negative | |
EV/Sales | 53.11 |
14 Analysts have issued a Protagonist Therapeutics, Inc. forecast for earnings per share. The average Protagonist Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Protagonist Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
JMP Securities |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 19 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
Wedbush |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
BMO Capital |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
Analyst Rating | Date |
---|---|
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 07 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Jun 17 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 03 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 19 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 10 2025 |
Locked
Wedbush:
Locked
➜
Locked
|
Mar 28 2025 |
Locked
BMO Capital:
Locked
➜
Locked
|
Mar 11 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.